Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Understanding and Exploiting PSMA Expression in Prostate Cancer Through the Development of Aptamer Based-PSMA Targeting
EF 2022-23
Résumé
PSMA (Prostate Specific Membrane Antigen) is a surface protein that is highly expressed in prostate cancer (PCa) with expression correlating with poor patient outcomes. PSMA is actively being developed as a therapeutic target, but current methods have significant limitations. PSMA therapies can have dose-limiting side effects due to PSMA present at other sites in the body and the linkages to radioactive payloads can be unstable. This project will overcome these issues by developing DNA-based PSMA-targeting aptamers, the size and specificity of which will limit access and binding to off-target PSMA, while the capacity for nanoparticle conjugation will enable more stable binding to radionuclides. Since I began work on this project, we have developed a series of lead candidate aptamers with an industry partner. Continuing this work, I will analyze modified versions of these aptamers to further optimize PCa-selective targeting. I will also identify the qualities of PSMA that are essential for binding of these aptamers to enable new strategies to improve specificity. Cells from the LNCaP PCa cell line with PSMA removed were used as a negative control during aptamer development and were found to exhibit a previously undescribed differential response to androgen deprived conditions. I will expand this panel of edited cell lines and describe molecular changes that occur in PSMA-deficient LNCaP cells as they adapt to androgen deprivation therapies. This proposal will identify first-in-class DNA aptamer agents able to selectively target PSMA, and define potential cellular adaptations likely to arise in response to prolonged PSMA-targeted therapies. These studies will allow us to better understand the role of PSMA in PCa, and better exploit it in PCa treatment.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486191
Name
Robinson Nicole
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding and Exploiting PSMA Expression in Prostate Cancer Through the Development of Aptamer Based-PSMA Targeting
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aptamers; Prostate Cancer; Psma; Radiotherapy; Theranostics
Abstract
PSMA (Prostate Specific Membrane Antigen) is a surface protein that is highly expressed in prostate cancer (PCa) with expression correlating with poor patient outcomes. PSMA is actively being developed as a therapeutic target, but current methods have significant limitations. PSMA therapies can have dose-limiting side effects due to PSMA present at other sites in the body and the linkages to radioactive payloads can be unstable. This project will overcome these issues by developing DNA-based PSMA-targeting aptamers, the size and specificity of which will limit access and binding to off-target PSMA, while the capacity for nanoparticle conjugation will enable more stable binding to radionuclides. Since I began work on this project, we have developed a series of lead candidate aptamers with an industry partner. Continuing this work, I will analyze modified versions of these aptamers to further optimize PCa-selective targeting. I will also identify the qualities of PSMA that are essential for binding of these aptamers to enable new strategies to improve specificity. Cells from the LNCaP PCa cell line with PSMA removed were used as a negative control during aptamer development and were found to exhibit a previously undescribed differential response to androgen deprived conditions. I will expand this panel of edited cell lines and describe molecular changes that occur in PSMA-deficient LNCaP cells as they adapt to androgen deprivation therapies. This proposal will identify first-in-class DNA aptamer agents able to selectively target PSMA, and define potential cellular adaptations likely to arise in response to prolonged PSMA-targeted therapies. These studies will allow us to better understand the role of PSMA in PCa, and better exploit it in PCa treatment.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Robinson, Nicole
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~